Stay updated on Fenebrutinib vs Teriflunomide in RMS Clinical Trial
Sign up to get notified when there's something new on the Fenebrutinib vs Teriflunomide in RMS Clinical Trial page.

Latest updates to the Fenebrutinib vs Teriflunomide in RMS Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page displays the study record for a Phase 3 trial comparing fenebrutinib with teriflunomide for relapsing multiple sclerosis, including participant criteria, study measures, and site locations. It replaces a forbidden-access error page.SummaryDifference100%

- Check17 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedAn NIH site-wide notice was added, announcing a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, and the standard header/footer are shown; this indicates access is blocked to the record.SummaryDifference17%

Stay in the know with updates to Fenebrutinib vs Teriflunomide in RMS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Teriflunomide in RMS Clinical Trial page.